Erlotinib plus ramucirumab (RAM) as first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation: phase 1B safety results and Phase 3 design of the ongoing Phase 1B/3 study RELAY

被引：0
|
作者：
Bischoff, H. [1 ]
Garon, E. B. [2 ]
Lee, P. [3 ]
He, S. [4 ]
Kropf-Sanchen, C. [5 ]
Kimmich, M. [6 ]
Nakagawa, K. [7 ]
Reck, M. [8 ]
机构：
[1] Univ Klinikum Heidelberg, Thoraxklin, Onkol Thoraxtumoren, Heidelberg, Germany
[2] Univ Calif Los Angeles, Med Ctr, Santa Monica, CA USA
[3] Eli Lilly & Co, Bridgewater, MA USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Univ Klinikum Ulm, Sekt Pneumol, Innere Med 2, Ulm, Germany
[6] Robert Bosch Krankenhaus, Klin Schillerhohe, Pneumol & Pneumol Onkol, Gerlingen, Germany
[7] Kinki Univ, Sch Med, Osaka, Japan
[8] German Ctr Lung Res DZL, LungenClin Grosshansdorf, ARCN, Grosshansdorf, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P593
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [31] Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
    Chu, Quincy
    Ciuleanu, Tudor
    Ramlau, Rodryg
    Renouf, Daniel
    Juergens, Rosalyn
    Kalinka, Ewa
    Sawrycki, Piotr
    Bramson, Jonathan
    Nelson, Brad
    Crabbe, Rafael
    Sahlender, Daniela A.
    Crompton, Philippa
    Rouits, Elisabeth
    Spaggiari, Dany
    Brichory, Franck
    Piggott, Luke
    Schenker, Mike
    Goss, Glenwood
    [J]. CANCER RESEARCH, 2023, 83 (08)
  • [32] A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
    Cho, Byoung Chul
    Goldberg, Sarah B.
    Kim, Dong-Wan
    Socinski, Mark A.
    Burns, Timothy F.
    Lwin, Zarnie
    Pathan, Nuzhat
    Ma, Wei Dong
    Masters, Joanna C.
    Cossons, Nandini
    Wilner, Keith
    Nishio, Makoto
    Husain, Hatim
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (07) : 747 - 757
  • [33] The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)
    Neal, J. W.
    Pennell, N. A.
    Govindan, R.
    Heist, R. S.
    Shaw, A. T.
    Muzikansky, A.
    Janne, P. A.
    Lynch, T. J.
    Azzoli, C. G.
    Sequist, L. V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S209 - S209
  • [34] The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Neal, Joel W.
    Pennell, Nathan A.
    Govindan, Ramaswamy
    Lanuti, Michael
    Rosovsky, Rachel Pam Greenerger
    Heist, Rebecca Suk
    Shaw, Alice Tsang
    Temel, Jennifer S.
    Muzikansky, Alona
    Janne, Pasi A.
    Lynch, Thomas James
    Azzoli, Christopher G.
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation
    Kanda, Shintaro
    Ohe, Yuichiro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Kubota, Kaoru
    Tamura, Tomohide
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Felip, Enriqueta
    Burotto, Mauricio
    Zvirbule, Zanete
    Herraez-Baranda, Luis A.
    Chanu, Pascal
    Kshirsagar, Smita
    Maiya, Vidya
    Chan, Phyllis
    Pozzi, Emanuela
    Marchand, Mathilde
    Monchalin, Marion
    Tanaka, Kunihiko
    Tosti, Nadia
    Wang, Bei
    Restuccia, Eleonora
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (10): : 1142 - 1155
  • [37] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
  • [38] Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study
    Besse, B.
    Garrido, P.
    Bennouna, J.
    Mezquita, L.
    Gazzah, A.
    Remon, J.
    Planchard, D.
    Olmedo Garcia, M. E.
    Raimbourg, J.
    Chao, G. Y.
    Gil, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [39] RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
    Nadal, Ernest
    Horinouchi, Hidehito
    Shih, Jin-Yuan
    Nakagawa, Kazuhiko
    Reck, Martin
    Garon, Edward B.
    Wei, Yu-Feng
    Kollmeier, Jens
    Frimodt-Moller, Bente
    Barrett, Emily
    Lipkovich, Olga
    Visseren-Grul, Carla
    Novello, Silvia
    [J]. DRUG SAFETY, 2022, 45 (01) : 45 - 64
  • [40] RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
    Ernest Nadal
    Hidehito Horinouchi
    Jin-Yuan Shih
    Kazuhiko Nakagawa
    Martin Reck
    Edward B. Garon
    Yu-Feng Wei
    Jens Kollmeier
    Bente Frimodt-Moller
    Emily Barrett
    Olga Lipkovich
    Carla Visseren-Grul
    Silvia Novello
    [J]. Drug Safety, 2022, 45 : 45 - 64
12345